

1 **Title**

2 Risk of Adverse Events Following Monovalent Third or Booster Dose of COVID-19 mRNA
3 Vaccination in U.S. Adults Ages 18 Years and Older

4 Azadeh Shoaibi, PhD, MHS,^{1*} Kathryn Matuska, BA,^{2*} Patricia C. Lloyd, PhD, ScM,¹ Hui Lee
5 Wong, PhD,¹ Joann F. Gruber, PhD,¹ Tainya C. Clarke, PhD,¹ Sylvia Cho, PhD,¹ Emily
6 Lassman, MS,² Hai Lyu, MS,² Rowan McEvoy, BS,² Zhiruo Wan, MSE,² Mao Hu, BS,² Sandia
7 Akhtar, BS,² Yixin Jiao, MPP,² Yoganand Chillarige, MPA,² Daniel Beachler, PhD,³ Alex
8 Secora, PhD,⁴ Nandini Selvam, PhD, MPH,⁴ Djeneba Audrey Djibo, PhD, MSBME,⁵ Cheryl N
9 McMahill Walraven, MSW, PhD,⁵ John D. Seeger, DrPH, PharmD,⁶ Kandace L. Amend, PhD,⁶
10 Jennifer Song, MA, MURP,⁶ Robin Clifford, MS, BS,⁶ Jeffrey A. Kelman, PhD,⁷ Richard A.
11 Forshee, PhD,¹ Steven A. Anderson, PhD¹

12 **Authors**

13 ¹US Food and Drug Administration, Silver Spring, MD, USA

14 ²Acumen LLC, Burlingame, CA, USA

15 ³Carelon Research, Wilmington, DE, USA

16 ⁴IQVIA, Falls Church, VA, USA

17 ⁵CVS Health/Aetna, Blue Bell, Pennsylvania, USA

18 ⁶Optum Epidemiology, Boston, MA, USA

19 ⁷Centers for Medicare & Medicaid Services, Washington, DC, USA

20

21 *First Authors

22 **Corresponding Author**

23 Patricia C. Lloyd, PhD, ScM
24 Office of Biostatistics and Pharmacovigilance
25 Center for Biologics Evaluation and Research
26 U.S. Food & Drug Administration
27 10903 New Hampshire Ave., Building 71
28 Silver Spring, MD 20993

29
30 Email: patricia.lloyd@fda.hhs.gov
31

32 **Manuscript Word Count**

33 2,960/3,000 words

34 **Abstract (248 words)**

35 **Background**

36 The U.S. FDA authorized the monovalent third primary series or booster doses of COVID-19
37 mRNA vaccines in August 2021 for persons 18 years and older. Monitoring of outcomes
38 following updated authorizations is critical to evaluate vaccine safety and can provide early
39 detection of rare adverse events (AEs) not identified in pre-licensure trials.

40 **Methods**

41 We evaluated the risk of 17 AEs following third doses of COVID-19 mRNA vaccines from
42 August 2021 through early 2022 among adults aged 18-64 years in three commercial databases
43 (Optum, Carelon Research, CVS Health) and adults aged >65 years in Medicare Fee-For-
44 Service. We compared observed AE incidence rates to historical (expected) rates prior to the
45 pandemic, estimated incidence rate ratios (IRRs) for the Medicare database and pooled IRR
46 across the three commercial databases. Analyses were also stratified by prior history of COVID-
47 19 diagnosis. Estimates exceeding a pre-defined threshold were considered statistical signals.

48 **Results**

49 Four AEs met the threshold for statistical signals for BNT162b2 and mRNA-1273 vaccines
50 including Bell's Palsy and pulmonary embolism in Medicare, and anaphylaxis and
51 myocarditis/pericarditis in commercial databases. Nine AEs and three AEs signaled among
52 adults with and without prior COVID-19 diagnosis, respectively.

53
54 **Conclusions**

55 This early monitoring study identified statistical signals for AEs following third doses of
56 COVID-19 mRNA vaccination. Since this method is intended for screening purposes and
57 generates crude results, results do not establish a causal association between the vaccines and
58 AEs. FDA's public health assessment remains consistent that the benefits of COVID-19
59 vaccination outweigh the risks of vaccination.

60 **Keywords**

61 COVID-19 mRNA vaccines, monovalent booster, Pfizer-BioNTech, Moderna, Medicare,
62 COVID-19 vaccine safety

63 **Introduction**

64 In the United States (U.S.), the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)
65 mRNA vaccines are available to prevent severe Coronavirus disease 2019 (COVID-19).^{1,2} For
66 monovalent formulations, third doses as primary series doses were recommended for persons
67 with immunocompromising conditions as of August 12, 2021, and a first booster dose (outside of
68 the primary series) was authorized through Emergency Use Authorization (EUA) by the U.S.
69 Food and Drug Administration (FDA) for everyone aged 18 years and older from November 19,
70 2021 to April 18, 2023. Statistical signals have been observed in active surveillance of the
71 monovalent mRNA vaccines.³⁻⁵ Thus, the FDA Biologics Effectiveness and Safety (BEST)
72 Initiative, an active surveillance program for post-market surveillance of biologic products,
73 conducted this study to investigate the safety of COVID-19 mRNA vaccines among individuals
74 aged 18 to 64 years in the commercially insured population and individuals aged 65 years and
75 older in the Medicare population by evaluating the rates of 17 adverse events (AEs) of interest
76 following third doses by comparing them to historical control (expected) rates for their
77 respective AEs. Results from this signal detection study do not establish a causal association
78 between the vaccines and AEs.

79 **Methods**

80 *Data Sources*

81 This study used administrative claims data from the Centers for Medicare & Medicaid Services
82 (CMS) Medicare (Fee-For-Service) database and from three commercial health insurance

83 databases: CVS Health, Optum pre-adjudicated claims, and Carelon Research (Supplemental
84 Table 1). The commercial data sources were supplemented with Immunization Information
85 System (IIS) data from local and state jurisdictions to increase the capture of vaccinations.⁶

86 ***Study Population and Period***

87 The study population included a commercially insured population (aged 18-64 years) and the
88 publicly insured Medicare Fee-For-Service population (aged 65 years and older) who received a
89 COVID-19 mRNA third dose vaccination from the study start date of August 12, 2021, when the
90 FDA authorized an additional vaccine dose for certain immunocompromised individuals,⁷
91 through database-specific study end dates. Data are included through April 2022 for Optum and
92 Carelon, February 2022 for CVS Health, and March 2022 for Medicare enrollees. For inclusion
93 in AE-specific analyses, persons must have been continuously enrolled in a medical health
94 insurance plan from the start of the AE-specific clean window through the date of their third
95 COVID-19 vaccine dose. This AE-specific pre-vaccination clean window was defined as a
96 specific number of days before vaccination date when a patient must not have had the AE (Table
97 1).

98 ***Exposure and Follow-Up***

99 Exposure was defined as the receipt of a third dose of the BNT162b2 COVID-19 or the mRNA-
100 1273 COVID-19 vaccine (Supplemental Table 2). Vaccinations were identified using brand and
101 dose-specific Current Procedural Terminology (CPT)/Healthcare Common Procedure Coding
102 System (HCPCS) codes or National Drug Codes (NDCs) in the professional, outpatient
103 institutional, inpatient, or prescription drug care settings,⁸ and were identified by CVX (vaccine
104 administered) product codes in IIS data sources.

105 Dose assignment was based on the chronological order in which vaccinations were observed for
106 each person. Third doses were restricted to doses following a two-dose primary series of mRNA
107 vaccines. If a patient was administered more than 3 doses of BNT162b2 or mRNA-1273 vaccine,
108 follow-up time was censored at the time of the fourth dose administration.

109 Patients who received heterologous vaccine brands for the primary series and third dose and
110 persons who received the first booster dose of Ad26.COVS.2 (Janssen) vaccine were included in
111 the descriptive analyses but not in the inferential analyses due to small sample size. First booster
112 doses of the Ad26.COVS.2 vaccine were restricted to doses following a one-dose primary series,
113 and follow-up time was censored at the time of administration if a patient was administered more
114 than 2 doses of Ad26.COVS.2.

115 Follow-up time began on the day after vaccination and was censored at death, disenrollment, end
116 of AE-specific risk window (Table 1), end of study period, a subsequent COVID-19 vaccine
117 dose, or at AE occurrence, whichever came first.

118 *Adverse Events of Interest*

119 Claims-based AE algorithms, pre-vaccination clean windows, and post-vaccination risk windows
120 were selected based on literature review and clinical consultation. All AEs (Table 1) were
121 identified using International Classification of Diseases, Tenth Revision, Clinical Modification
122 (ICD-10-CM) diagnosis codes.⁸ Claims from inpatient facilities (IP), emergency department
123 encounters in outpatient facilities (OP-ED), and all outpatient facilities and individual providers
124 or professionals (OP/PB) were used to identify AEs.

125 *Statistical Analyses*

126 The vaccine dose count was summarized by brand for each AE (Table 2). The count and
127 proportion of heterologous vaccine brand administration of third doses was also summarized.
128 This study was designed as a retrospective cohort analysis with a historical comparator group.
129 The primary analysis compared the observed rate of the AE of interest in the post-vaccination
130 risk window to the rate in a database-specific historical control population, and incidence rate
131 ratios (IRR) were estimated. The observed rate of each AE was adjusted based on observation
132 delay for that outcome in 2019 using a similar approach as described in the literature for partially
133 accrued data.⁹ We calculated database-specific comparator rates as the annual AE rates within
134 the overall and influenza-vaccinated populations in the pre-COVID-19 (2017-2019) and during-
135 COVID-19 pandemic (June 2020-December 10, 2020) periods. The comparator rate used for the
136 analysis was selected to enhance the sensitivity of the test for signal detection. If annual rates in
137 the historical period differed, as assessed by comparing the 95% confidence intervals (CI), we
138 selected the lowest rate; otherwise, the median annual rate was selected. Pre-COVID-19 rates
139 from 2019 were selected for most outcomes; however, when the during-COVID-19 rate (June-
140 December 10, 2020) did not return to pre-COVID-19 levels, rates from 2020 were selected.⁸
141 There were no adjustments for baseline clinical characteristics. Comparator rates were generated
142 stratified by age and sex when sufficient counts in the respective strata were available in all
143 databases. Also, comparator rates were generated by nursing home residency status and race in
144 the Medicare population only.

145 Analyses for myocarditis/pericarditis were stratified by care setting (all settings and IP/OP-ED
146 settings) and age (18-45 years and 46-64 years) in the commercially insured population to more
147 granularly assess risk based on prior evidence regarding increased risk of

148 myocarditis/pericarditis following COVID-19 mRNA vaccination particularly amongst younger
149 males.¹⁰⁻²²

150 For each potential AE, Poisson models were used to estimate the incidence rate (IR) per 100,000
151 person-years with 95% CI and the IRR of observed IR vs. expected IR with 95% CI. One-sided
152 tests were conducted with an overall alpha of 2.5% and with testing margins selected for each
153 AE based on clinical significance and expert guidance to avoid detection of false-positive results
154 and characterization of non-clinically meaningful, minimal risk increases. In the commercially
155 insured population, the null hypotheses were IRR = 1.5 for anaphylaxis, transverse myelitis, and
156 myocarditis/pericarditis; 2.5 for encephalitis or encephalomyelitis, narcolepsy, and Guillain-
157 Barré syndrome (GBS); and 1.25 for all other outcomes. To detect any increase in risk in the
158 Medicare population, in which outcomes are more common, more sensitive tests were conducted
159 where the null hypothesis was IRR = 1 for all AEs. A statistical signal occurred if the observed
160 IRR exceeded the null hypothesis and the null hypothesis was not within the IRR 95% CI which
161 was used as a threshold for determining whether the result was likely to occur due to chance.
162 Statistical testing was only conducted for individuals who received the same vaccine brand for
163 primary series and third doses.

164 To account for prior COVID-19 infection as a potential confounder, we conducted a secondary
165 analysis for each AE stratified by history of COVID-19 diagnosis identified by diagnosis of
166 COVID-19 in any care setting (identified by U07.1 ICD-10-CM code) on or following April 1,
167 2020.

168 IRs and IRRs were generated for the Medicare database separately and pooled across the three
169 commercial databases using meta-analysis with a random-effects and fixed-effects models.
170 Between-study heterogeneity was assessed using a I^2 statistic.²³

171 **Results**

172 *Descriptive Analyses*

173 Across the commercial insurance databases, 3,803,442 beneficiaries received BNT162b2 and
174 2,400,502 beneficiaries received mRNA-1273 third dose vaccines. The count of vaccine doses
175 was summarized by brand for each AE for all COVID-19 vaccines (Table 2) and AE-specific
176 analyses (Supplemental Table 3). A large proportion of third doses was mRNA vaccines; we did
177 not conduct inferential analyses on the Ad26.COV2.S vaccine due to the small number of doses
178 administered. Approximately 64% - 83% of vaccinations across brands in commercial databases
179 were eligible for the analysis and contributed to an AE-specific cohort. In the Medicare database,
180 3,336,862 beneficiaries received BNT162b2 and 3,399,048 beneficiaries received mRNA-1273
181 third dose vaccines; more than 90% of these vaccinations across brands were eligible for the
182 analysis and contributed to an AE-specific cohort (Supplemental Table 3). Less than 13% of
183 cases with an observed AE across databases had an associated prior COVID-19 diagnosis
184 (Supplemental Table 4, Supplemental Table 5). Most people received the same vaccine brand for
185 primary series and third doses (Supplemental Table 6).

186 *Results of Primary and Secondary Analyses – Persons 18 to 64 years*

187 Among the 17 AEs of interest evaluated in the commercially insured population, two AEs met
188 the threshold for a statistical signal in primary analyses. A signal was observed post-BNT162b2
189 third dose vaccination for anaphylaxis (IRR = 4.92, 95% CI = 2.20–10.98). Following mRNA-

190 1273 third dose vaccination, signals were observed for anaphylaxis (IRR = 5.70, 95% CI = 1.69–
191 19.21) and myocarditis/pericarditis: IP/OP-ED (18-45 years) (IRR = 3.38, 95% CI = 1.51–7.58)
192 (Table 3).

193 In the secondary analyses stratified by prior COVID-19 diagnosis, statistical signals were
194 observed in the population with a prior COVID-19 diagnosis following BNT162b2 third dose
195 vaccination for anaphylaxis (IRR= 37.26, 95% CI = 6.69–207.58); encephalitis or
196 encephalomyelitis (IRR= 26.85, 95% CI = 7.43 – 96.99); and unusual site TTS (IRR= 8.43, 95%
197 CI = 1.51–46.96) (Supplemental Table 4). The following statistical signals were observed
198 following mRNA-1273 third dose vaccination: myocarditis/pericarditis, all settings for 18-45
199 years (IRR= 7.22, 95% CI = 2.58–20.19) and 46-64 years (IRR= 6.61, 95% CI = 3.26–13.41);
200 myocarditis/pericarditis, IP/OP-ED settings for 46-64 years (IRR= 11.35, 95% CI = 4.06–31.74);
201 common site thrombosis with thrombocytopenia (TTS) (IRR= 5.83, 95% CI = 2.28–14.92); and
202 GBS (IRR= 18.19, 95% CI = 3.26–101.35).

203 In the population without a prior history of COVID-19 diagnosis, a signal was observed post-
204 BNT162b2 third dose vaccination for anaphylaxis (IRR= 6.21, 95% CI = 2.50–15.39). In
205 addition, signals were observed post-mRNA-1273 third dose vaccinations for
206 myocarditis/pericarditis, IP/OP-ED settings for 18-45 years (IRR= 3.63, 95% CI = 1.62–8.15);
207 and anaphylaxis (IRR= 6.15, 95% CI = 1.82–20.71) (Supplemental Table 4).

208 ***Results of Primary and Secondary Analyses –Persons 65 years and older***

209 Statistical signals were observed for two AEs in the primary analysis in the Medicare population
210 following third dose vaccinations. Statistical signals were identified following BNT162b2 third
211 dose vaccinations for Bell’s Palsy (BP) (IRR = 1.11, 95% CI = 1.03 – 1.19) and pulmonary

212 embolism (PE) (IRR = 1.05, 95% CI = 1.001 – 1.100) (Table 4). No signals were identified
213 following mRNA-1273 third dose vaccinations (Table 4).

214 In the secondary analyses stratified by prior COVID-19 diagnosis, five AEs met the threshold for
215 a statistical signal. In the population with a prior COVID-19 diagnosis, signals were observed for
216 PE following BNT162b2 (IRR = 1.36, 95% CI = 1.17–1.58) and mRNA-1273 third dose
217 vaccinations (IRR = 1.43, 95% CI = 1.20–1.69); acute myocardial infarction (AMI) following
218 BNT162b2 (IRR = 1.15, 95% CI = 1.02–1.29) and mRNA-1273 third dose vaccinations (IRR =
219 1.33, 95% CI = 1.16–1.52). In addition, following BNT162b2 third dose vaccination, signals
220 were observed for immune thrombocytopenia (ITP) (IRR = 1.66, 95% CI = 1.17–2.29) and
221 myocarditis/pericarditis (IRR = 1.89, 95% CI = 1.18–2.86).

222 In the population without a prior history of COVID-19 diagnosis, a signal was observed for BP
223 (IRR = 1.11, 95% CI = 1.03–1.19) following BNT162b2 third dose vaccination (Supplemental
224 Table 6). While more AEs of interest with elevated risk were observed in the secondary analysis
225 compared to the primary analysis, smaller sample sizes reflected wider 95% CI estimates
226 (Supplemental Tables 4-5).

227 **Discussion**

228 In this large population-based study we investigated the safety of third doses of COVID-19
229 mRNA vaccines by examining the risk of 17 AEs following vaccination in a signal detection
230 study as the first step in the safety surveillance process.

231 The primary analyses of the study found statistical signals for four AEs. Myocarditis/pericarditis
232 and anaphylaxis have been reported to be associated with the primary doses of vaccines.<sup>3,4,8,10-
233 ^{22,24} There is a high level of outcome misclassification (a non-case being identified as a case or</sup>

234 vice versa) associated with the detection of BP cases and hence uncertainty with its signal as
235 results from a medical record review (MRR) of a sample of BP cases in our other COVID-19
236 vaccine studies showed a low positive predictive value (PPV) (<20%, data not shown) of the
237 claims-based diagnosis codes used to identify cases indicating that most cases resulting in the
238 signal were not true cases. The PE signal was marginal and similar to inconsistent results
239 detected in previous COVID-19 vaccine safety studies where a protective effect following third
240 doses of both mRNA brands and a small statistically significant elevated risk following
241 BNT162b2 primary series were observed for PE.²⁴

242 Among those with a prior COVID-19 diagnosis, nine AEs signaled. Most of these AEs have
243 been reported to be associated with COVID-19 infection itself.²⁵⁻²⁷ In adults aged 18-64 years, all
244 signals in populations with and without prior COVID-19 diagnosis arose from a small number of
245 cases. Similar to BP, our MRR of ITP cases in other COVID-19 vaccines safety studies
246 suggested a low PPV (<10%, data not shown) of the claims-based diagnosis codes used to
247 identify cases indicating that most cases identified for inclusion were not true cases. Moreover,
248 given the small number of cases, wide 95% CIs, and IRRs that are unadjusted for confounders,
249 these signals carry a high level of uncertainty and should be interpreted cautiously.

250 In the population without a prior COVID-19 diagnosis, three AEs signaled. The BP signal may
251 be explained by potential outcome misclassification, and the anaphylaxis and
252 myocarditis/pericarditis signals are consistent with the current literature.^{3,10-15}

253 This study has several strengths. The study included a large U.S. adult population covered by
254 commercial insurance or Fee-For-Service Medicare. Because of the large sample size, the study
255 had higher power to detect a smaller increase in risk of rare AEs after vaccination that may not

256 be captured in pre-authorization clinical trials. Linkage of the commercial administrative claims
257 databases to the IIS databases captured more COVID-19 vaccines administered. The
258 retrospective cohort design with the use of historical comparator group allowed a rapid safety
259 evaluation of vaccines as the first step in the active surveillance process.

260 There are several limitations in this study. Aggregate historical rates rather than individuals were
261 used as the comparator which increases the potential for confounding and bias. Thus, the study
262 results are crude or unadjusted for confounders, and do not establish a causal relationship
263 between the vaccines and AEs. The stratified results should also be interpreted in the context of
264 uncertainty and with caution. Although this study design was unable to disentangle the effect of
265 prior COVID-19 infection and COVID-19 vaccines on the rates of AEs, several AEs which
266 signaled in the population with a prior history of COVID-19 diagnosis are known to be
267 associated with COVID-19 infection.²⁵⁻²⁷ Therefore, it is likely that a number of detected signals
268 from these crude results may be associated with the prior history of COVID-19 diagnosis.

269 In this study, AEs were identified by diagnosis codes in claims databases which are subject to
270 coding errors, and the study did not conduct MRR for all AEs to verify the true cases. Thus,
271 outcome misclassification cannot be ruled out and could also bias results. The misclassification
272 also applies to detection of prior COVID-19 infection in claims databases for the same reason as
273 well as others such as use of home tests or not seeking medical care for the infection. Several
274 identified signals arose from a very small number of AE cases. AE risk intervals were pre-
275 specified based on literature review and clinical input, but their misspecification could lead to
276 bias. The large sample size, inclusion of many AEs, and the number of statistical tests could
277 increase the probability of false-positive results. Additionally, our study may not have captured
278 all COVID-19 vaccines administered as some people may have received vaccines from sources

279 that did not submit claims to insurance carriers, such as mass vaccination sites. Lastly, the results
280 of this study may not be generalizable to the portion of the U.S. population who is uninsured or
281 carries other types of health insurance.

282 Since the authorization or approval of the mRNA vaccines that were evaluated in this study,
283 there have been additional FDA authorizations of COVID-19 vaccines. This study did not
284 include second booster doses authorized for those 50 years and older or those 12 years and older
285 with certain immunocompromised conditions (authorized March 29, 2022), third doses for
286 children ages 5 to 11 years (authorized May 17, 2022), or bivalent booster doses for individuals
287 12 years and older (authorized August 31, 2022) as these vaccines were not yet authorized for
288 use at the time this study was conducted.^{1,28-30} Active safety surveillance is ongoing to expand
289 the monitoring of AEs to include individuals who receive these vaccinations.

290 In conclusion, this signal detection study detected multiple signals after exposure to the third
291 dose of COVID-19 mRNA vaccines. The results of this study must be interpreted in the context
292 of the study design, statistical methods, and their limitations; thus, some of the safety signals
293 detected may be false positive results. While this study has major limitations, it contributes to the
294 signal detection phase in the multi-step surveillance process for COVID-19 mRNA vaccines.
295 FDA's public health assessment remains consistent that the benefits of COVID-19 vaccination
296 outweigh the risks of COVID-19 disease, and safety surveillance of new COVID-19 vaccines is
297 ongoing.

Tables

Table 1. Study Specifications: Adverse Events (AEs), Care Settings, Clean Windows, and Risk Windows for the Medicare and Commercial Databases

Adverse Events	Care Setting	Clean Window	Risk Window
Acute Myocardial Infarction	IP	365 days	1-28 days ^{31,32}
Anaphylaxis	IP, OP-ED	30 days	0-1 days ^{33,34}
Appendicitis	IP, OP-ED	365 days	1-42 days ^{35,36}
Bell's Palsy	IP, OP/PB	183 days	1-42 days ³⁷
Common Site Thrombosis with Thrombocytopenia Syndrome†	IP, OP/PB	365 days	1-28 days ³⁸
Deep vein thrombosis	IP, OP/PB	365 days	1-28 days ^{39,40}
Disseminated Intravascular Coagulation	IP, OP-ED	365 days	1-28 days ⁴¹
Encephalitis or Encephalomyelitis	IP	183 days	1-42 days ⁴²
Guillain-Barré Syndrome	IP- primary position only	365 days	1-42 days ^{43,44}
Hemorrhagic Stroke	IP	365 days	1-28 days ^{31,32}
Immune Thrombocytopenia	IP, OP/PB	365 days	1-42 days ^{45,46}
Myocarditis/Pericarditis	IP, OP/PB	365 days	1-21 days ⁴⁷
	IP, OP-ED**	365 days	1-21 days ⁴⁷
Narcolepsy	IP, OP/PB	365 days	1-42 days ⁴⁸⁻⁵⁰
Non-hemorrhagic Stroke	IP	365 days	1-28 days ^{31,32}
Pulmonary Embolism	IP, OP/PB	365 days	1-28 days ^{39,40}
Transverse Myelitis	IP, OP-ED	365 days	1-42 days ⁵¹
Unusual Site Thrombosis with Thrombocytopenia Syndrome †	IP, OP-ED	365 days	1-28 days ⁵²

Definitions: Clean window was an interval used to define incident outcomes where an individual entered the study cohort only if the AE did not occur during that interval. The anchor date of the clean window was the date of third or booster dose vaccination. Risk window was an interval during which occurrence of the AE would be included in the analyses. All risk windows were selected based on input from clinicians and observations from the primary series analyses.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

***Only included in the commercial claims analyses*

†Both common site thrombosis with thrombocytopenia syndrome and unusual site thrombosis with thrombocytopenia syndrome were composite outcomes consisting of a thrombotic event (composed of other events such as acute myocardial infarction, deep vein thrombosis etc.,) and a thrombocytopenia event (defined in the IP, OP/PB setting). The overall setting definition for each outcome depended on individual setting definitions for each of these components.

Table 2. Number of Third COVID-19 Vaccine Doses Administered Stratified by Adverse Event and Vaccine Brand

Adverse Event	Vaccine Brand*	Optum (data through 4/2022)	Carelon Research (data through 4/2022)	CVS Health (data through 2/2022)	CMS (data through 3/2022)
Acute Myocardial Infarction	Overall	1,689,421	2,139,967	1,351,973	6,251,603
	BNT162b2	1,000,053	1,329,255	797,434	3,044,019
	mRNA-1273	660,412	771,677	534,648	3,130,235
	Ad26.COV2.S	24,714	37,638	18,699	77,349
Anaphylaxis	Overall	1,927,599	2,345,700	1,638,582	6,480,438
	BNT162b2	1,140,207	1,455,706	967,037	3,161,023
	mRNA-1273	753,975	846,246	647,516	3,238,065
	Ad26.COV2.S	28,577	42,200	22,627	81,350
Appendicitis	Overall	1,688,969	2,139,815	1,351,792	6,294,970
	BNT162b2	999,710	1,329,114	797,320	3,066,139
	mRNA-1273	660,294	771,644	534,571	3,150,874
	Ad26.COV2.S	24,726	37,659	18,708	77,957
Bell's Palsy	Overall	1,858,202	2,322,687	1,519,376	6,449,310
	BNT162b2	1,099,406	1,441,734	896,440	3,145,205
	mRNA-1273	726,841	838,198	600,541	3,223,344
	Ad26.COV2.S	27,261	41,243	21,071	80,761
Common Site Thrombosis with Thrombocytopenia Syndrome	Overall	1,690,750	2,141,767	1,353,047	6,285,282
	BNT162b2	1,000,825	1,330,319	798,052	3,060,858
	mRNA-1273	660,943	772,364	535,076	3,146,593
	Ad26.COV2.S	24,738	37,686	18,724	77,831
Deep Vein Thrombosis	Overall	1,684,942	2,134,016	1,348,081	6,195,088
	BNT162b2	997,418	1,325,657	795,204	3,013,969
	mRNA-1273	658,639	769,424	533,046	3,104,233
	Ad26.COV2.S	24,656	37,542	18,643	76,886
Disseminated Intravascular Coagulation	Overall	1,691,142	2,142,258	1,353,408	6,299,613
	BNT162b2	1,001,048	1,330,623	798,250	3,068,400
	mRNA-1273	661,097	772,545	535,229	3,153,195
	Ad26.COV2.S	24,752	37,692	18,733	78,018
Encephalitis or Encephalomyelitis	Overall	1,859,342	2,324,304	1,520,448	6,459,403
	BNT162b2	1,100,043	1,442,692	897,030	3,150,231
	mRNA-1273	727,319	838,829	601,003	3,228,290
	Ad26.COV2.S	27,283	41,270	21,090	80,882
Guillain-Barré Syndrome	Overall	1,691,168	2,142,321	1,353,443	6,299,987
	BNT162b2	1,001,069	1,330,662	798,277	3,068,597
	mRNA-1273	661,102	772,566	535,237	3,153,369
	Ad26.COV2.S	24,752	37,695	18,733	78,021
Hemorrhagic Stroke	Overall	1,690,947	2,142,083	1,353,243	6,294,837
	BNT162b2	1,000,939	1,330,523	798,170	3,065,877
	mRNA-1273	661,015	772,470	535,147	3,151,005
	Ad26.COV2.S	24,748	37,692	18,730	77,955
Immune Thrombocytopenia	Overall	1,690,045	2,140,779	1,352,500	6,286,013
	BNT162b2	1,000,389	1,329,681	797,718	3,061,612
	mRNA-1273	660,673	772,028	534,867	3,146,522
	Ad26.COV2.S	24,738	37,673	18,720	77,879
Myocarditis/Pericarditis	Overall	1,690,317	2,141,214	1,352,672	6,293,962
	BNT162b2	1,000,523	1,329,975	797,820	3,065,519
	mRNA-1273	660,808	772,161	534,939	3,150,486
	Ad26.COV2.S	24,742	37,682	18,718	77,957
Narcolepsy	Overall	1,689,745	2,140,143	1,352,291	6,294,962

Adverse Event	Vaccine Brand*	Optum (data through 4/2022)	Carelon Research (data through 4/2022)	CVS Health (data through 2/2022)	CMS (data through 3/2022)
	BNT162b2	1,000,279	1,329,369	797,646	3,066,033
	mRNA-1273	660,493	771,724	534,728	3,150,965
	Ad26.COVS.S	24,730	37,653	18,721	77,964
Non-hemorrhagic Stroke	Overall	1,690,389	2,141,279	1,352,772	6,271,813
	BNT162b2	1,000,577	1,330,013	797,888	3,053,779
	mRNA-1273	660,826	772,195	534,969	3,140,346
	Ad26.COVS.S	24,741	37,674	18,719	77,688
Pulmonary Embolism	Overall	1,686,537	2,136,235	1,349,614	6,222,146
	BNT162b2	998,322	1,326,934	796,022	3,028,297
	mRNA-1273	659,274	770,309	533,725	3,116,714
	Ad26.COVS.S	24,703	37,600	18,675	77,135
Transverse Myelitis	Overall	1,691,160	2,142,311	1,353,437	6,299,944
	BNT162b2	1,117,841	1,330,661	798,274	3,068,584
	mRNA-1273	661,100	772,557	535,234	3,153,341
	Ad26.COVS.S	24,752	37,695	18,733	78,019
Unusual Site Thrombosis with Thrombocytopenia Syndrome	Overall	1,691,155	2,142,284	1,353,417	6,299,696
	BNT162b2	1,001,068	1,330,637	798,262	3,068,441
	mRNA-1273	661,090	772,554	535,226	3,153,238
	Ad26.COVS.S	24,752	37,695	18,733	78,017

**BNT162b2 and mRNA-1273 vaccine doses do not add up to 'Overall' due to vaccination-days with multiple products.*

Table 3. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 18–64 Years Old Enrolled in Commercial Insurance (Meta-Analyzed across Commercial Databases)

Adverse Events	Vaccine Brand	No. Observed Cases	IRR (95% CI)
Acute Myocardial Infarction	BNT162b2	186	0.82 (0.71 – 0.95)
	mRNA-1273	140	0.97 (0.82 – 1.14)
Anaphylaxis	BNT162b2	<11	4.92* (2.20 – 10.98)
	mRNA-1273	<11	5.70* (1.69 – 19.21)
Appendicitis	BNT162b2	295	0.95 (0.73 – 1.25)
	mRNA-1273	164	0.89 (0.66 – 1.21)
Bell’s Palsy	BNT162b2	331	0.97 (0.83 – 1.13)
	mRNA-1273	173	0.84 (0.62 – 1.13)
Common Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	43	0.82 (0.61 – 1.11)
	mRNA-1273	25	0.68 (0.23 – 2.04)
Deep Vein Thrombosis	BNT162b2	357	0.76 (0.66 – 0.88)
	mRNA-1273	258	0.87 (0.77 – 0.99)
Disseminated Intravascular Coagulation	BNT162b2	<11	0.94 (0.49 – 1.80)
	mRNA-1273	<11	1.22 (0.54 – 2.78)
Encephalitis or Encephalomyelitis	BNT162b2	12	2.28 (0.96 – 5.43)
	mRNA-1273	<11	1.28 (0.53 – 3.09)
Guillain-Barré Syndrome	BNT162b2	<11	0.82 (0.37 – 1.84)
	mRNA-1273	<11	2.75 (0.76 – 9.95)
Hemorrhagic Stroke	BNT162b2	32	0.92 (0.48 – 1.74)
	mRNA-1273	17	0.85 (0.53 – 1.34)
Immune Thrombocytopenia	BNT162b2	91	1.03 (0.70 – 1.52)
	mRNA-1273	51	0.99 (0.65 – 1.50)
Myocarditis/Pericarditis: All Care Settings (18-45 years of age)	BNT162b2	41	1.95 (1.38 – 2.75)
	mRNA-1273	24	2.19 (1.08 – 4.48)
Myocarditis/Pericarditis: All Care Settings (46-64 years of age)	BNT162b2	38	1.23 (0.90 – 1.68)
	mRNA-1273	34	1.69 (1.21 – 2.35)
Myocarditis/Pericarditis: IP/OP-ED (18-45 years of age)	BNT162b2	15	2.31 (1.19 – 4.51)
	mRNA-1273	11	3.38* (1.51 – 7.58)
Myocarditis/Pericarditis: IP/OP-ED (46-64 years of age)	BNT162b2	<11	1.01 (0.52 – 1.93)
	mRNA-1273	12	2.38 (1.24 – 4.56)
Narcolepsy	BNT162b2	96	0.82 (0.59 – 1.13)
	mRNA-1273	57	0.89 (0.62 – 1.27)
Non-hemorrhagic Stroke	BNT162b2	97	0.8 (0.55 – 1.17)
	mRNA-1273	65	0.82 (0.64 – 1.04)
Pulmonary Embolism	BNT162b2	309	1.01 (0.91 – 1.13)
	mRNA-1273	181	0.97 (0.81 – 1.15)
Transverse Myelitis	BNT162b2	<11	0.98 (0.29 – 3.31)
	mRNA-1273	<11	1.23 (0.36 – 4.14)
Unusual Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	<11	0.66 (0.24 – 1.78)
	mRNA-1273	<11	0.94 (0.28 – 3.16)

**Indicates the adverse event for the specific vaccine brand has signaled in the analyses.*

Cell sizes 1-10 were masked for confidentiality.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

Table 4. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 65 Years and Older Enrolled in Medicare

Adverse Events	Vaccine Brand	No. Vaccine Doses	No. Observed Cases	Observed Person-Time (Years)	IRR (95% CI)
Acute Myocardial Infarction	BNT162b2	3,044,019	2,478	214,600	0.89 (0.85 – 0.92)
	mRNA-1273	3,130,235	2,434	216,853	0.9 (0.86 – 0.94)
Anaphylaxis	BNT162b2	3,161,023	<11	16,338	2.12 (0.44 – 6.20)
	mRNA-1273	3,238,065	<11	16,535	0 (0.00 – 2.53)
Appendicitis	BNT162b2	3,066,139	239	318,926	0.95 (0.83 – 1.08)
	mRNA-1273	3,150,874	258	320,221	1.01 (0.89 – 1.14)
Bell’s Palsy	BNT162b2	3,145,205	803	334,038	1.11* (1.03 – 1.19)
	mRNA-1273	3,223,344	722	336,386	1 (0.93 – 1.08)
Common Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	3,060,858	737	224,291	0.91 (0.84 – 0.98)
	mRNA-1273	3,146,593	708	227,919	0.88 (0.82 – 0.95)
Deep Vein Thrombosis	BNT162b2	3,013,969	2,298	215,607	0.78 (0.75 – 0.81)
	mRNA-1273	3,104,233	2,026	218,817	0.71 (0.68 – 0.74)
Disseminated Intravascular Coagulation	BNT162b2	3,068,400	63	208,306	0.83 (0.64 – 1.06)
	mRNA-1273	3,153,195	53	208,026	0.72 (0.54 – 0.95)
Encephalomyelitis	BNT162b2	3,150,231	38	316,355	1.37 (0.97 – 1.89)
	mRNA-1273	3,228,290	33	312,678	1.23 (0.85 – 1.73)
Guillain-Barré Syndrome	BNT162b2	3,068,597	12	311,896	0.86 (0.45 – 1.51)
	mRNA-1273	3,153,369	<11	310,292	0.72 (0.34 – 1.32)
Hemorrhagic Stroke	BNT162b2	3,065,877	393	213,982	0.87 (0.79 – 0.96)
	mRNA-1273	3,151,005	370	215,414	0.85 (0.76 – 0.94)
Immune Thrombocytopenia	BNT162b2	3,061,612	333	328,185	1.11 (0.99 – 1.24)
	mRNA-1273	3,146,522	322	332,293	1.07 (0.96 – 1.20)
Myocarditis/Pericarditis	BNT162b2	3,065,519	161	165,642	1.09 (0.93 – 1.27)
	mRNA-1273	3,150,486	144	167,882	0.98 (0.82 – 1.15)
Narcolepsy	BNT162b2	3,066,033	135	324,439	1.12 (0.94 – 1.32)
	mRNA-1273	3,150,965	93	327,554	0.77 (0.62 – 0.94)
Non-hemorrhagic Stroke	BNT162b2	3,053,779	1,427	214,901	0.76 (0.72 – 0.80)
	mRNA-1273	3,140,346	1,389	217,119	0.77 (0.73 – 0.81)
Pulmonary Embolism	BNT162b2	3,028,297	1,749	217,775	1.05* (1.001 – 1.100)
	mRNA-1273	3,116,714	1,649	221,084	1 (0.95 – 1.05)
Transverse Myelitis	BNT162b2	3,068,584	17	317,121	1.57 (0.92 – 2.52)
	mRNA-1273	3,153,341	<11	317,588	0.56 (0.21 – 1.23)
Unusual Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	3,068,441	28	223,602	1.27 (0.84 – 1.83)
	mRNA-1273	3,153,238	20	226,866	0.88 (0.54 – 1.36)

**Indicates the adverse event for the specific vaccine brand has signaled in the analyses.*

Medicare database contains data through March 2022.

Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 1. Description of Characteristics of Administrative Claims Data Sources Used in the Study

Data Source		Update frequency	Claims Data Lag	Enrollees
Centers for Medicare & Medicaid Services (CMS) administrative claims data source	Medicare Fee-For-Service	Weekly	Approximately 80% data completeness in 1-3 months for inpatient, outpatient, and professional claims	~48 million totals from 2017-2021 ~33 million annually
Commercial claims data sources	CVS Health	Monthly	Approximately 80% data completeness in 3-4 months for inpatient claims, 2-3 months for outpatient claims, and 1-2 months for	~37 million total from 2018-2021 ~22 million annually
	Optum Pre-Adjudicated Claims	Bi-Weekly	Approximately 80% data completeness in 1-2 months for inpatient, outpatient, and professional claims	~29 million total from 2017-2021 ~15-16 million annually
	Carelon Research	Monthly	Approximately 80% data completeness in 2-3 months for inpatient claims and 1-2 months for outpatient and professional claims	~46 million total from 2016-2021 ~24 million annually

Supplemental Table 2. COVID-19 Vaccine Emergency Use Authorization (EUA) Dates and Dose Schedule Recommendations

Manufacturer	Name	Vaccine Authorization Dates ¹		Dosing Interval ^{2,7,29,30,53}
Pfizer-BioNTech	BNT162b2 BNT162b2-BioNTech COVID-19 Vaccine	1 st Dose	12/11/2020	- 21 days between doses 1, 2
		2 nd Dose	12/11/2020	- 28 days between doses 2, 3
		3 rd Dose	8/12/2021	- 5 months between primary series and booster dose
		1 st Monovalent Booster	9/22/2021	- 4 months between first and second booster doses
		2 nd Monovalent Booster	3/29/2022	
		Bivalent Booster Dose	8/31/2022	
Moderna	mRNA-1273 COVID-19 Vaccine	1 st Dose	12/18/2020	- 28 days between doses 1, 2
		2 nd Dose	12/18/2020	- 28 days between doses 2, 3
		3 rd Dose	8/12/2021	- 5 months between primary series and booster dose
		1 st Monovalent Booster	10/20/2021	- 4 months between first and second booster doses
		2 nd Monovalent Booster	3/29/2022	
		Bivalent Booster Dose	8/31/2022	
Janssen	Ad26.COV2.S COVID-19	1 st Dose	2/27/2021	- 2 months between primary series and booster dose
		Monovalent Booster	10/20/2022	

Supplemental Table 3. Number of Third COVID-19 mRNA Vaccine Doses Included in Adverse Event Specific Analyses

Adverse Events	No. Third Vaccine Doses							
	Optum		Carelon Research		CVS Health		CMS	
	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273	BNT162b2	mRNA-1273
Total No. Doses	1,280,591	845,142	1,458,076	847,366	1,064,775	707,993	3,336,862	3,399,048
Total No. Doses Satisfying Criteria*								
Acute Myocardial Infarction	927,568	547,891	1,092,311	621,495	730,364	424,230	3,044,019	3,130,235
Anaphylaxis	1,056,780	624,702	1,196,966	679,812	884,991	512,462	3,161,023	3,238,065
Appendicitis	927,255	547,821	1,092,238	621,550	730,282	424,237	3,066,139	3,150,874
Bell's Palsy	1,019,227	602,273	1,186,633	673,853	821,224	476,422	3,145,205	3,223,344
Common Site Thrombosis with Thrombocytopenia Syndrome	928,298	548,354	1,093,202	622,103	730,940	424,599	3,060,858	3,146,593
Deep Vein Thrombosis	925,149	546,338	1,089,291	619,631	728,300	422,902	3,013,969	3,104,233
Disseminated Intravascular Coagulation	928,501	548,491	1,093,456	622,250	731,126	424,728	3,068,400	3,153,195
Encephalitis or Encephalomyelitis	1,019,811	602,672	1,187,445	674,369	821,778	476,788	3,150,231	3,228,290
Guillain-Barré Syndrome	928,522	548,498	1,093,491	622,268	731,152	424,733	3,068,597	3,153,369
Hemorrhagic Stroke	928,411	548,417	1,093,370	622,183	731,047	424,657	3,065,877	3,151,005
Immune Thrombocytopenia	927,897	548,125	1,092,660	621,808	730,622	424,419	3,061,612	3,146,522
Myocarditis/Pericarditis: All Care Settings	928,015	548,249	1,092,916	621,947	730,731	424,495	3,065,519	3,150,486
Myocarditis/Pericarditis: IP/OP-ED Settings**	928,446	548,454	1,093,371	622,206	731,084	424,704	NA	NA
Narcolepsy	927,790	547,981	1,092,465	621,591	730,583	424,352	3,066,033	3,150,965
Non-hemorrhagic Stroke	928,079	548,247	1,092,941	621,961	730,797	424,504	3,053,779	3,140,346
Pulmonary Embolism	925,962	546,894	1,090,407	620,352	729,067	423,457	3,028,297	3,116,714
Transverse Myelitis	928,516	548,495	1,093,491	622,259	731,148	424,731	3,068,584	3,153,341
Unusual Site Thrombosis with Thrombocytopenia Syndrome	928,520	548,486	1,093,471	622,254	731,136	424,726	3,068,441	3,153,238

*Total numbers of mRNA vaccine doses administered by brand that satisfied analysis inclusion criteria for each adverse event.

**Analyses for myocarditis/pericarditis stratified by care setting were not conducted in the Medicare database. NA means not applicable.

Care Settings Definition: IP referred to inpatient facility claims. OP-ED referred to a subset of outpatient facility claims occurring in the emergency department. OP/PB referred to all outpatient facility claims, and professional/provider claims except those professional/provider claims with a laboratory place of service.

Supplemental Table 4. Incidence Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 18-64 Years Old Enrolled in Commercial Insurance Databases, Stratified by Prior COVID-19 Diagnosis, Meta-Analyzed for Commercial Claims Databases

Adverse Events	Vaccine Brand	With Prior COVID-19 Diagnosis		Without Prior COVID-19 Diagnosis	
		No. Observed Cases	IRR (95% CI)	No. Observed Cases	IRR (95% CI)
Acute Myocardial Infarction	BNT162b2	22	1.32 (0.88– 1.99)	164	0.79 (0.68 – 0.92)
	mRNA-1273	13	1.35 (0.70 – 2.57)	127	0.95 (0.80 – 1.13)
Anaphylaxis	BNT162b2	<11	37.26* (6.69 – 207.58)	<11	6.21* (2.50 – 15.39)
	mRNA-1273	0	NA	<11	6.15* (1.82 – 20.71)
Appendicitis	BNT162b2	29	1.22 (0.86 – 1.75)	266	0.93 (0.71 – 1.23)
	mRNA-1273	17	1.12 (0.28 – 4.46)	147	0.87 (0.68 – 1.10)
Bell’s Palsy	BNT162b2	38	1.42 (0.83 – 2.45)	293	0.93 (0.77 – 1.12)
	mRNA-1273	17	0.95 (0.26 – 3.49)	156	0.82 (0.64 – 1.04)
Common Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	<11	1.01 (0.42 – 2.44)	39	0.81 (0.60 – 1.11)
	mRNA-1273	<11	5.83* (2.28 – 14.92)	21	0.66 (0.27 – 1.65)
Deep Vein Thrombosis	BNT162b2	46	1.27 (0.90 – 1.77)	311	0.72 (0.63 – 0.81)
	mRNA-1273	32	1.54 (0.96 – 2.47)	226	0.83 (0.73 – 0.94)
Disseminated Intravascular Coagulation	BNT162b2	<11	4.26 (0.76 – 23.74)	<11	0.95 (0.48 – 1.91)
	mRNA-1273	0	NA	<11	1.31 (0.58 – 2.99)
Encephalitis or Encephalomyelitis	BNT162b2	<11	26.85* (7.43 – 96.99)	<11	1.98 (1.10 – 3.58)
	mRNA-1273	0	NA	<11	1.37 (0.57 – 3.31)
Guillain-Barré Syndrome	BNT162b2	<11	4.91 (0.88 – 27.35)	<11	0.76 (0.32 – 1.84)
	mRNA-1273	<11	18.19* (3.26 – 101.35)	<11	1.49 (0.27 – 8.30)
Hemorrhagic Stroke	BNT162b2	<11	1.7 (0.61 – 4.76)	29	0.93 (0.54 – 1.62)
	mRNA-1273	<11	2.22 (0.66 – 7.48)	15	0.8 (0.49 – 1.30)
Immune Thrombocytopenia	BNT162b2	<11	1.14 (0.56 – 2.31)	84	1.03 (0.72 – 1.48)
	mRNA-1273	<11	1.24 (0.44 – 3.46)	48	1.01 (0.68 – 1.51)
Myocarditis/Pericarditis: All Care Settings (18-45 years of age)	BNT162b2	<11	2.65 (0.95 – 7.41)	38	1.96 (1.32 – 2.93)
	mRNA-1273	<11	7.22* (2.58 – 20.19)	21	2.09 (1.16 – 3.77)
Myocarditis/Pericarditis: All Care Settings (46-64 years of age)	BNT162b2	<11	1.22 (0.45 – 3.28)	35	1.23 (0.89 – 1.71)
	mRNA-1273	<11	6.61* (3.26 – 13.41)	27	1.45 (1.00 – 2.10)
Myocarditis/Pericarditis: IP/OP-ED (18-45 years of age)	BNT162b2	0	NA	15	2.5 (1.28 – 4.85)
	mRNA-1273	0	NA	<11	3.63* (1.62 – 8.15)
Myocarditis/Pericarditis: IP/OP-ED (46-64 years of age)	BNT162b2	<11	4.66 (0.84 – 25.98)	<11	1.02 (0.51 – 2.04)
	mRNA-1273	<11	11.35* (4.06 – 31.74)	<11	2.03 (1.09 – 3.77)
Narcolepsy	BNT162b2	12	1.12 (0.39 – 3.23)	84	0.8 (0.63 – 1.02)
	mRNA-1273	<11	1.05 (0.47 – 2.34)	52	0.88 (0.59 – 1.31)
Non-hemorrhagic Stroke	BNT162b2	<11	0.53 (0.24 – 1.18)	92	0.82 (0.55 – 1.24)
	mRNA-1273	<11	1.69 (0.91 – 3.13)	56	0.77 (0.59 – 0.99)
Pulmonary Embolism	BNT162b2	28	1.08 (0.51 – 2.28)	281	1 (0.89 – 1.13)
	mRNA-1273	14	1.06 (0.64 – 1.77)	167	0.97 (0.78 – 1.20)
Transverse Myelitis	BNT162b2	0	NA	<11	1.06 (0.32 – 3.59)
	mRNA-1273	0	NA	<11	1.32 (0.39 – 4.44)
Unusual Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	<11	8.43* (1.51 – 46.96)	<11	0.73 (0.22 – 2.47)
	mRNA-1273	0	NA	<11	1.01 (0.30 – 3.39)

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses.

Cells with ‘NA’ indicate adverse events for which an IRR (95% CI) could not be estimated due to zero observed cases.

Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 5. Incident Rate Ratio (IRR) and 95% Confidence Interval (CI) of Adverse Events Following a Third Dose of COVID-19 mRNA Vaccine Among Adults 65 Years and Older Enrolled in Medicare, Stratified by Prior COVID-19 Diagnosis

Adverse Events	Vaccine Brand	With Prior COVID-19 Diagnosis			Without Prior COVID-19 Diagnosis		
		No. Observed Cases	Observed Person-Time (Years)	IRR (95% CI)	No. Observed Cases	Observed Person-Time (Years)	IRR (95% CI)
Acute Myocardial Infarction	BNT162b2	274	14,705	1.15* (1.02 – 1.29)	2204	199,895	0.86 (0.83 – 0.90)
	mRNA-1273	216	11,396	1.33* (1.16 – 1.52)	2,218	205,457	0.87 (0.84 – 0.91)
Anaphylaxis	BNT162b2	0	1,140	0 (0.00 – 41.98)	<11	15,198	2.26 (0.47 – 6.61)
	mRNA-1273	0	888	0 (0.00 – 49.92)	0	15,647	0 (0.00 – 2.66)
Appendicitis	BNT162b2	21	21,878	1.31 (0.81 – 2.01)	218	297,048	0.93 (0.81 – 1.06)
	mRNA-1273	<11	16,796	0.85 (0.42 – 1.52)	247	303,425	1.02 (0.89 – 1.15)
Bell's Palsy	BNT162b2	60	22,881	1.14 (0.87 – 1.47)	743	311,158	1.11* (1.03 – 1.19)
	mRNA-1273	48	17,662	1.23 (0.91 – 1.63)	674	318,725	0.99 (0.91 – 1.06)
Common Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	83	15,514	1.23 (0.98 – 1.52)	654	208,777	0.88 (0.81 – 0.95)
	mRNA-1273	57	12,076	1.19 (0.90 – 1.54)	651	215,843	0.86 (0.80 – 0.93)
Deep Vein Thrombosis	BNT162b2	261	14,696	1 (0.88 – 1.13)	2,037	200,912	0.76 (0.73 – 0.79)
	mRNA-1273	166	11,516	0.94 (0.80 – 1.09)	1,860	207,301	0.7 (0.66 – 0.73)
Disseminated Intravascular Coagulation	BNT162b2	0	14,267	0 (0.00 – 0.54)	63	194,039	0.91 (0.70 – 1.16)
	mRNA-1273	<11	10,888	1.53 (0.61 – 3.15)	46	197,137	0.67 (0.49 – 0.89)
Encephalitis or Encephalomyelitis	BNT162b2	<11	21,208	1.33 (0.27 – 3.88)	35	295,147	1.38 (0.96 – 1.92)
	mRNA-1273	<11	15,949	1.3 (0.16 – 4.68)	31	296,728	1.23 (0.83 – 1.74)
Guillain-Barré Syndrome	BNT162b2	0	21,093	0 (0.00 – 4.22)	12	290,803	0.92 (0.48 – 1.61)
	mRNA-1273	0	15,939	0 (0.00 – 5.36)	<11	294,353	0.75 (0.36 – 1.39)
Hemorrhagic Stroke	BNT162b2	40	14,759	1.06 (0.76 – 1.45)	353	199,223	0.85 (0.77 – 0.95)
	mRNA-1273	26	11,382	1 (0.65 – 1.47)	344	204,032	0.84 (0.75 – 0.93)
Immune Thrombocytopenia	BNT162b2	37	22,705	1.66* (1.17 – 2.29)	296	305,480	1.07 (0.95 – 1.20)
	mRNA-1273	17	17,624	1.02 (0.59 – 1.63)	305	314,669	1.08 (0.96 – 1.20)
Myocarditis/Pericarditis	BNT162b2	22	11,554	1.89* (1.18 – 2.86)	139	154,087	1.02 (0.86 – 1.21)
	mRNA-1273	13	9,000	1.53 (0.81 – 2.62)	131	158,882	0.94 (0.79 – 1.12)
Narcolepsy	BNT162b2	12	22,422	1.26 (0.65 – 2.19)	123	302,017	1.1 (0.92 – 1.32)
	mRNA-1273	<11	17,356	0.72 (0.23 – 1.68)	88	310,198	0.77 (0.62 – 0.95)
Non-hemorrhagic Stroke	BNT162b2	158	14,825	1 (0.85 – 1.17)	1,269	200,076	0.74 (0.70 – 0.78)
	mRNA-1273	101	11,486	0.93 (0.76 – 1.13)	1,288	205,633	0.76 (0.72 – 0.80)
Pulmonary Embolism	BNT162b2	182	14,951	1.36* (1.17 – 1.58)	1,567	202,824	1.02 (0.97 – 1.07)
	mRNA-1273	137	11,671	1.43* (1.20 – 1.69)	1,512	209,413	0.98 (0.93 – 1.03)
Transverse Myelitis	BNT162b2	<11	21,625	2.21 (0.27 – 7.99)	15	295,496	1.51 (0.85 – 2.50)
	mRNA-1273	<11	16,502	3.19 (0.39 – 11.53)	<11	301,087	0.4 (0.11 – 1.02)
Unusual Site Thrombosis with Thrombocytopenia Syndrome	BNT162b2	<11	15,472	2.63 (0.72 – 6.74)	24	208,130	1.17 (0.75 – 1.73)
	mRNA-1273	<11	11,997	0.83 (0.02 – 4.65)	19	214,869	0.88 (0.53 – 1.38)

*Indicates the adverse event for the specific vaccine brand has signaled in the analyses.

Medicare database contains data through March 2022.

Cell sizes 1-10 were masked for confidentiality.

Supplemental Table 6. Number of COVID-19 Homologous and Heterologous Third Vaccine Doses Administered Following Primary Series

Vaccine Brand	Optum	Carelon Research	CVS Health	CMS
	No. Vaccinees (%)	No. Vaccinees (%)	No. Vaccinees (%)	No. Vaccinees (%)
Primary Series: BNT162b2	1,182,306	1,326,121	1,023,199	5,208,339
Total third vaccine doses among BNT162b2 primary series recipients	1,182,306 (100.00)	1,326,121 (100.00)	1,023,199 (100.00)	3,243,792 (100.00)
Ad26.COVS booster doses	--	--	--	3,301 (0.10)
BNT162b2 third vaccine doses	1,062,247 (89.85)	1,198,742 (90.39)	903,546 (88.31)	3,136,719 (96.70)
mRNA-1273 third vaccine doses	120,059 (10.15)	127,379 (9.61)	119,653 (11.69)	103,772 (3.20)
Primary Series: mRNA-1273	700,210	768,750	585,837	5,233,843
Total third vaccine doses among mRNA-1273 primary series recipients	700,210 (100.00)	768,750 (100.00)	585,837 (100.00)	3,370,141 (100.00)
Ad26.COVS booster doses	--	--	--	6,259 (0.19)
BNT162b2 third vaccine doses	72,499 (10.35)	88,046 (11.45)	62,976 (10.75)	149,253 (4.43)
mRNA-1273 third vaccine doses	627,711 (89.65)	680,704 (88.55)	522,861 (89.25)	3,214,629 (95.39)
Primary Series: Ad26.COVS	37,610	42,855	26,700	541,723
Total third vaccine doses among Ad26.COVS primary series recipients	37,610 (100.00)	42,855 (100.00)	26,700 (100.00)	211,684 (100.00)
Ad26.COVS booster doses	25,480 (67.75)	35,565 (82.99)	21,411 (80.19)	80,147 (37.86)
BNT162b2 third vaccine doses	6,318 (16.80)	3,715 (8.67)	2,340 (8.76)	50,890 (24.04)
mRNA-1273 third vaccine doses	5,812 (15.45)	3,575 (8.34)	2,949 (11.04)	80,647 (38.10)

Conflicts of Interest

All authors have no conflicts of interest to disclose.

Ethics Statement

As a public health surveillance activity, this study was not subject to requirements for Institutional Review Board review.

Authorship Contributions

All authors contributed to the concept and design of the study and interpretation of the data. A. Shoaibi drafted the manuscript and all authors reviewed it. K. Matuska, H. Lyu, R. McEvoy, Z. Wan, M. Hu, D. Beachler, A. Secora, N. Selvam, D. Djibo, C. McMahill-Walraven, J. Seeger, K. Amend, J. Song, R. Clifford, R. Forshee, and S. Anderson acquired and managed the data and performed analyses. The views expressed here are those of the authors and not necessarily those of the U.S. Food and Drug Administration, the Centers for Medicare and Medicaid Services, the Department of Health and Human Services, CVS Health/Aetna, Carelon Research, IQVIA, or Optum Epidemiology. This work has not been presented publicly, previously published, or is under current consideration by another journal.

Funding

There were no extra-institutional sources of funding.

Acknowledgments

We would like to thank Gyanada Acharya, Derick Ambarsoomzadeh, Mahasweta Mitra, Michelle Ondari, Ellie Smith, and Zoe Wu from Acumen LLC; Shiva Vojjala, Ramya Avula, Shiva Chaudhary, Qian Si, Dianna Hayden, Shanthi P Sagare, Ramin Riahi, Brian Greenwald, and Grace Stockbower from Carelon Research; Michael Goodman, Michael Bruhn, and Ruth Weed from IQVIA; Anne Marie Kline, Nancy B. Shaik, Ana M. Martinez-Baquero, Smita Bhatia, Carla Brannan, Vaibhav Sharma, Eugenio Abente, and Jonathan Deshazo from CVS Health; and Grace Yang, Sarah Sargen, Alexandra Stone, Wafa Tarazi, Megan Ketchell, Kathryn Federici, Amaka Ume, Emily Myers, Eli Wolter, Jackson Slaney, Bobby Smith, Lauren Peetluk, and Elizabeth Bell from Optum for their assistance with data validation, analysis, manuscript preparation, and project coordination.

References

1. FDA C. COVID-19 Vaccines. *Coronavirus Disease 2019 (COVID-19)* 2022; <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines?msclkid=2b8a54e5b49e11ecb160a21c546d50fa>. Accessed 04/04/2022, 2022.
2. Administration USFaD. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers); Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19). In. FDA Media 2022.
3. Wong H-L, Tworkoski E, Zhou CK, et al. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older. *SSRN*. 2022.
4. Lloyd P, Hu M, Wong H-L, et al. Near real-time surveillance of safety outcomes in US COVID-19 vaccine recipients aged 12 to 64 years. *Vaccine*. 2022.
5. Cirillo N, Doan R. The association between COVID-19 vaccination and Bell's Palsy. *The Lancet Infectious Diseases*. 2022;22(1):5-6.
6. Prevention CfDca. Immunization Information Systems (IIS). 2019.
7. Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals [press release]. U.S. FDA Press Announcements August 12, 2021 2021.
8. Administration USFaD. Safety Assessment of 3rd Dose/Booster Dose of COVID-19 mRNA Vaccines: Master Protocol. 2022.
9. Greene SK, Kulldorff M, Yin R, et al. Near real-time vaccine safety surveillance with partially accrued data. *Pharmacoepidemiology and drug safety*. 2011;20(6):583-590.
10. EMA E. Signal assessment report on myocarditis and pericarditis with Spikevax - COVID-19 mRNA vaccine (nucleosidemodified). In: Committee PRA, ed. European Medicines Authority Science Medicines Health2021.
11. Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. *N Engl J Med*. 2021;385(23):2140-2149.
12. PHO. Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to April 3, 2022 In: Ontario PH, ed. Media Documents2022.
13. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *JAMA*. 2022;327(4):331-340.
14. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. *Jama*. 2021;326(12):1210-1212.
15. Kim HW, Jenista ER, Wendell DC, et al. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. *JAMA Cardiol*. 2021;6(10):1196-1201.
16. Marshall M, Ferguson ID, Lewis P, et al. Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. *Pediatrics*. 2021;148(3).
17. Montgomery J, Ryan M, Engler R, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*. 2021;6(10):1202-1206.
18. Rosner CM, Genovese L, Tehrani BN, et al. Myocarditis Temporally Associated With COVID-19 Vaccination. *Circulation*. 2021;144(6):502-505.

19. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. *Bmj*. 2021;375:e068665.
20. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nat Med*. 2022;28(2):410-422.
21. Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *N Engl J Med*. 2021;385(23):2132-2139.
22. Vaccines and Related Biological Products Advisory Committee October 14-15, 2021 Meeting Announcement [press release]. Vaccine Adisory Committee Meeting Calendar, October 14-15 2021 2021.
23. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine*. 2002;21(11):1539-1558.
24. Shoaibi A, Lloyd PC, Wong H-L, et al. Evaluation of potential adverse events following COVID-19 mRNA vaccination among adults aged 65 years and older: Two self-controlled studies in the U.S. *Vaccine*. 2023;41(32):4666-4678.
25. Burn E, Li X, Delmestri A. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2: a population-based cohort analysis. *medRxiv*. 2021.
26. Ho FK, Man KKC, Toshner M, et al. Thromboembolic Risk in Hospitalized and Nonhospitalized COVID-19 Patients: A Self-Controlled Case Series Analysis of a Nationwide Cohort. *Mayo Clinic Proceedings*. 2021;96(10).
27. Barda N, Dagan N, Ben-Shlomo Y. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med*. 2021.
28. Coronavirus (COVID-19) Update: FDA Authorizes Second Booster Dose of Two COVID-19 Vaccines for Older and Immunocompromised Individuals [press release]. FDA News Release, March 29, 2022 2022.
29. CDC Recommends Pfizer Booster at 5 months, Additional Primary Dose for Certain Immunocompromised Children [press release]. CDC Newsroom January 4, 2022 2022.
30. Administration USFaD. Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose. 2022.
31. Al Qudah Z, Abukwaik W, Souayah N. Stroke after Vaccination in United States. A Report from the CDC/FDA Vaccine Adverse Event Reporting System. [1990–2010] (P01.009). *Neurology*. 2012;78(1 Supplement):P01.009-P001.009.
32. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. *New England Journal of Medicine*. 2004;351(25):2611-2618.
33. Rüggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2007;25(31):5675-5684.
34. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. *Journal of Allergy and Clinical Immunology*. 2019;143(4):1465-1473.
35. Donahue JG, Kieke BA, Lewis EM, et al. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. *Pediatrics*. 2019;144(6):e20191808.

36. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. *Vaccine*. 2011;29(46):8279-8284.
37. Loucie Renoud eA. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. *N Engl J Med*. 2021;384(1):20-30.
38. Pishko AM, Bussel JB, Cines DB. COVID-19 vaccination and immune thrombocytopenia. *Nat Med*. 2021;27(7):1145-1146.
39. Kearon C. Natural history of venous thromboembolism. *Circulation*. 2003;107(23_suppl_1):I-22-I-30.
40. Kearon C, Akl EA. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. *Blood*. 2014;123(12):1794-1801.
41. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. *Journal of Thrombosis Haemostasis*. 2020;18(4):844-847.
42. Pellegrino P, Carnovale C, Perrone V, et al. Acute disseminated encephalomyelitis onset: evaluation based on vaccine adverse events reporting systems. *PloS one*. 2013;8(10):e77766.
43. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barré syndrome following vaccination in the national influenza immunization program, United States, 1976–1977. *American Journal of Epidemiology*. 1979;110(2):105-123.
44. Dodd CN, Romio SA, Black S, et al. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines. *Vaccine*. 2013;31(40):4448-4458.
45. Black C, Kaye JA, Jick H. MMR vaccine and idiopathic thrombocytopenic purpura. *British Journal of Clinical Pharmacology*. 2003;55(1):107-111.
46. D'alò GL, Zorzoli E, Capanna A, et al. Frequently asked questions on seven rare adverse events following immunization. *Journal of Preventive Medicine Hygiene*. 2017;58(1):E13.
47. Klein NP. Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and “Head-to-Head” Product Comparisons. Paper presented at: ACIP Meetings; October 21, 2021, 2021.
48. Duffy J, Weintraub E, Vellozzi C, DeStefano F. Narcolepsy and influenza A (H1N1) pandemic 2009 vaccination in the United States. *Neurology*. 2014;83(20):1823-1830.
49. Montplaisir J, Petit D, Quinn M-J, et al. Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. *PloS one*. 2014;9(9):e108489.
50. Sarkanen TO, Alakuijala AP, Dauvilliers YA, Partinen MM. Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis. *Sleep Medicine Reviews*. 2018;38:177-186.
51. Agmon-Levin N, Kivity S, Szyper-Kravitz M, Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. *Lupus*. 2009;18(13):1198-1204.
52. Whitworth HeA. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. *Blood*. 2021;138(2):190-198.
53. Administration USFaD. Vaccine Information Fact Sheet for Recipients and Caregivers About Spikevax (COVID-19) Vaccine, mRNA) and the Moderna COVID-19 Vaccine to

Prevent Coronavirus Disease: 2019 (COVID-19) in Individuals 18 Years of Age and Older. In. FDA Media 2022.